- Catalog
- 2023 North America Conference on Lung Cancer (NACL ...
2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts
Conference | English | 2023
|
|
Credit Offered:
|
No Credit Offered
|
|
PP01.01 (Poster) High-risk histopathological correlates of stage I non-small cell lung cancer (NSCLC) outcomes
|
|
PP01.02 (Poster) Clinical characteristics and outcomes of patients with EGFR mutated non-small cell lung cancer treated by EGFR targeted therapy then immunotherapy
|
|
PP01.05 (Poster) Treatment Patterns and Healthcare Resource Utilization of Non-small Cell Lung Cancer Patients in Puerto Rico: The TREATLINES-ONCOLUNG Study
|
|
PP01.116 (Poster) Utilization of Extended-interval, Fixed-dosing of Durvalumab, Every 4 weeks, in U.S. Patients with Unresectable Stage III NSCLC Following Concurrent Chemoradiation
|
|
PP01.07 (Poster)Agent -Based Modeling Approach for Screening Cancer Growth
|
|
PP01.09 (Poster) Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US
|
|
PP01.10 (Poster) Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data
|
|
PP01.101 (Poster) Estimated Cost of Adverse Events and Surgery for Patients With Resectable Non small Cell Lung Cancer Who Are Receiving Neoadjuvant Nivolumab Plus Platinum Doublet Chemotherapy
|
|
PP01.102 (Poster) Appalachian Veterans Lung Cancer Screening Program
|
|
PP01.104 (Poster) Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases
|
|
PP01.105 (Poster) Early detection of non–small-cell lung cancer using electronic health record data
|
|
PP01.106 (Poster) Validation of Immunotherapy Response Score (IRS) for predicting pembrolizumab monotherapy benefit in first line (1L) non-small cell lung cancer (NSCLC)
|
|
PP01.107 (Poster) Patient Characteristics and Treatment Patterns in Biomarker-Selected Early Non-Small Cell Lung Cancer
|
|
PP01.108 (Poster) Randomized Control Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer
|
|
PP01.109 (Poster) Concordance of Breast Density Between Low-Dose CT and Mammogram
|
|
PP01.11 (Poster) Real-world Treatment Patterns and Outcomes Among Unresectable Stage III Non-Small Cell Lung Cancer
|
|
PP01.110 (Poster) The Relationship Between Social Determinants of Health and Treatment Patterns and Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer
|
|
PP01.111 (Poster) Phase 2a Intratumoral Large Surface Area Microparticle Paclitaxel in Stage 3/4 Lung Cancer
|
|
PP01.112 (Poster) Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study
|
|
PP01.113 (Poster) Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
|
|
PP01.114 (Poster) Outcomes of Patients Diagnosed with Lung Cancer after COVID 19 Infection
|
|
PP01.115 (Poster) Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer and HER2 Mutations
|
|
PP01.117 (Poster) Real-World Effectiveness and Safety Pro le of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer
|
|
PP01.119 (Poster) Real-World Use of Lurbinectedin in Patients With Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis
|
|
PP01.120 (Poster) Pre-diagnostic Serum Biomarkers With Prognostic Value for Lung Cancer
|
|
PP01.121 (Poster) Analysis of Degron Disruption in Small Cell Lung Cancer
|
|
PP01.122 (Poster) Inclusion of Patients with Brain Metastases and Leptomeningeal Disease in Phase 3 Lung Cancer Clinical Trials: Time for Action
|
|
PP01.124 (Poster) Impact of Comprehensive vs. Limited NGS on Time to Result and Time to Treatment in Advanced NSCLC
|
|
PP01.126 (Poster) PP01.126 Lobectomy versus Sublobar Resection in the population based Mid South Quality of Surgical Resection (MS QSR) Cohort
|
|
PP01.127 (Poster) A rare case of pulmonary enteric adenocarcinoma in a 26-year-old female non-smoker
|
|
PP01.12 (Poster) Quality of Smoking Cessation Counseling Provided by Artificial Intelligence Voice Assistants
|
|
PP01.129 (Poster) Effects of Preoperative Hematocrit Level on Perioperative Outcomes and Overall Survival after Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy
|
|
PP01.13 (Poster) Healthcare Utilization Amongst Patients with NSCLC Before and After Testing with a Host Immune Classifier (HIC) in a Real-World Setting
|
|
PP01.130 (Poster) Associations between Postoperative Hematocrit Levels and Postoperative Outcomes after Robotic-Assisted Pulmonary Lobectomy
|
|
PP01.131 (Poster) The Lee Revised Cardiac Risk Index as a Predictor of Postoperative Complications and Survival after Robotic-Assisted Pulmonary Lobectomy
|
|
PP01.132 (Poster) Auto-Segmentation of Lung Tumors Using Deep Learning Engines
|
|
PP01.133 (Poster) Clinical and Economic Outcomes Associated with Genomic Testing Strategies in Real World Data in Advanced Non Small Cell Lung Cancer (aNSCLC)
|
|
PP01.134 (Poster) Pathologist Driven Reflex Testing Provides Rapid, Orthogonal Results to NSCLC Patients in Response to Comprehensive Genomic Profiling QNS
|
|
PP01.135 (Poster) Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III: A Multi Center Study
|
|
PP01.136 (Poster) Understanding Experiences of Cancer Related Fatigue in Patients with Lung Cancer After Their Cancer Treatment A Qualitative Content Analysis
|
|
PP01.137 (Poster) Survival of Patients with Early-Stage Non-Small Cell Lung Cancer (NSCLC) Diagnosed at a Safety-Net Hospital
|
|
PP01.138 (Poster) Reporting of Sociodemographic Variables in Epidemiologic Studies of Non-Small Cell Lung Cancer: A Systematic Review
|
|
PP01.139 (Poster) Cardiac Events Following Concurrent Chemotherapy and Radiation with Durvalumab Consolidation for Unresectable Non-Metastatic Non-Small Cell Lung Cancer
|
|
PP01.14 (Poster) Healthcare Utilization Amongst Patients with NSCLC Stratified by Metastatic Status Before and After Testing with a Host Immune Classifier (HIC)
|
|
PP01.140 (Poster) Patient Preferences for EGFRExon 20 Insertion-Targeted Therapies in NSCLC: A Multi-Dimensional Thresholding Analysis
|
|
PP01.15 (Poster) Healthcare Costs Amongst Patients with Non-Small Cell lung cancer (NSCLC) Before and After Testing with a Host Immune Classifier (HIC)
|
|
PP01.16 (Poster) Evaluation of Lines of Therapy Amongst Patients with NSCLC Tested with a Host Immune Classifier (HIC) in a Real-World Setting
|
|
PP01.169 (Poster) Promotion of Low-Dose Computed Tomography Screening and Blood Biomarkers in Minority Communities for Early Detection of Lung Cancer in Northern Illinois
|
|
PP01.17 (Poster) Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelioma-Like Carcinoma
|
|
PP01.170 (Poster) The Role of Fat Mass and Obesity-Associated (FTO) Gene in Non-small Cell Lung Cancer Tumorigenicity and EGFR Tyrosine Kinase Inhibitor Resistance
|
|
PP01.172 (Poster) It is never too late to quit. A review: Smoking cessation can impact outcomes at all stages
|
|
PP01.18 (Poster) Real-world evaluation of racial and socioeconomic disparities in patients with NSCLC treated with immunotherapy
|
|
PP01.19 (Poster) Comparison of AI models in Lung Cancer Diagnosis and Staging
|
|
PP01.20 (Poster) Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy
|
|
PP01.21 (Poster) Five years of operation report on asbestos-related lung cancer surveillance system centered on general hospitals in South Korea
|
|
PP01.22 (Poster) Single Institution Experience of MRI Guided Radiotherapy for Thoracic Tumors and Clinical Characteristics Impacting Treatment Duty Cycle
|
|
PP01.23 (Poster) Plasma cell-free RNA PD-L1 or Tissue PD-L1 Protein Expression and Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer
|
|
PP01.24 (Poster) FURVENT: Global, Phase 3 Trial Testing Furmonertinib versus Chemotherapy as First Line Treatment for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
|
|
PP01.25 (Poster) BURDEN OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION ON PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) FROM THE PERSPECTIVE OF PATIENTS AND CAREGIVERS
|
|
PP01.26 (Poster) Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis
|
|
PP01.27 (Poster) Segmentectomy quality remains important in GGO dominant stage I lung cancer
|
|
PP01.30 (Poster) Integration of molecular cancer classification and NGS to identify patients with cancer of unknown primary (CUP) and other unclear diagnoses eligible for KRAS inhibitors
|
|
PP01.31 (Poster) Impact of Targeted Pathology Education Designed to Address Challenges in Biomarker Testing and Treatment for NSCLC
|
|
PP01.33 (Poster) Comparison of Baseline Risk of Developing and Dying from Lung Cancer in Screen Eligible General Versus Trial Populations
|
|
PP01.34 (Poster) Quantifying Minimal Residual Disease in Patients with Limited Stage Small Cell Lung Cancer
|
|
PP01.36 (Poster) Applying a Lung Cancer Screening Model on a Real-World Population
|
|
PP01.38 (Poster) A Missed Opportunity, The Lack of Lung Cancer Clinical Trial Promotion on Instagram by NCI Designated Cancer Centers
|
|
PP01.39 (Poster) Demographic and Socioeconomic Disparities in Lung Cancer Screening Uptake: A Quantitative Analysis in the State of Indiana
|
|
PP01.40 (Poster) Treatment Patterns and Survival Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Survival at a Safety-Net Hospital
|
|
PP01.41 (Poster) Clinical Trial Enrollment Success of Underrepresented Patients with Lung Cancer at a Single Institution
|
|
PP01.42 (Poster) Mutation/ Co-mutation Characteristics and Clinical Outcomes for Lung Adenocarcinoma with EGFR Germline Mutations
|
|
PP01.44 (Poster) A CT IMAGING BIOMARKER FOR CD8+ LYMPHOCYTES INFILTRATION STRATIFICATION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
|
|
PP01.45 (Poster) Associations of health-related quality of life (HRQoL) with daily functioning and communication with care teams in patients with ALK+ NSCLC
|
|
PP01.46 (Poster) Real-World Rebiopsy and Biomarker Retesting Rates Among Patients With Non–Small Cell Lung Cancer Across Patient Demographics in the United States
|
|
PP01.47 (Poster) TREAT 2.0 – Creation of a Clinically Useful High-Risk Lung Nodule Calculator
|
|
PP01.49 (Poster) END TO END MODEL FOR NODULE DETECTION AND CHARACTERIZATION IN LUNG CANCER SCREENING: PERFORMANCES AND SUBPOPULATION ANALYSIS
|
|
PP01.50 (Poster) SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression and / or Amplification Post-Osimertinib
|
|
PP01.52 (Poster) The Effect of Altered RNA Expression on Tumor Immune Infiltration in NSCLC: A Retrospective NGS Study
|
|
PP01.54 (Poster) A Multicenter, Open-Label Phase 1 Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Advanced Solid Tumors
|
|
PP01.55 (Poster) Patient-reported experience as a baseline for 4R care sequence implementation at 9 cancer centers
|
|
PP01.57 (Poster) Understanding the molecular mechanism of Supinoxin on Small cell Lung Cancer Therapy
|
|
PP01.58 (Poster) Real-World Outcomes in Patients INTRODUCTION METHODS With EGFR Wildtype Nonsquamous Locally Advanced/ Metastatic NSCLC Receiving Second- or Third-Line Docetaxel: Pooled Analysis From LUMINATE-101
|
|
PP01.59 (Poster) Minimal Short-Term Mortality in a Diverse, Real-World Lung Cancer Screening Cohort
|
|
PP01.60 (Poster) Nodify Lung Risk Assessment Testing in Deciphering the Risk of Malignancy of a Lung Nodule
|
|
PP01.61 (Poster) The Use of Low-Dose Lung CT for Lung Cancer Screening in Firefighters
|
|
PP01.62 (Poster) Downregulation of Immune-Mediated Pathways in Lung Andenocarcinoma with KEAP1 or STK11 Mutation
|
|
PP01.63 (Poster) A comparative analysis of plasma genotyping practices in non-small cell lung cancer by race, ethnicity, and smoking status
|
|
PP01.64 (Poster) Disparities in the impact of advances in metastatic non-small cell lung cancer therapy on mortality in the United States
|
|
PP01.65 (Poster) Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib
|
|
PP01.66 (Poster) An unusual presentation and delayed diagnosis of multifocal lung adenocarcinoma
|
|
PP01.67 (Poster) Evaluating Immune-Related Adverse Events in A Real-world Cohort with Lung Cancer Receiving Immunotherapy
|
|
PP01.68 (Poster)Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy
|
|
PP01.69 (Poster) Atypical Lung Carcinoids with EML4::ALK Fusion and Responses to ALK Inhibitors
|
|
PP01.70 (Poster) Next Generation of Bronchoscopy for Diagnostic Evaluation of Non-Small Cell Lung Cancer
|
|
PP01.71 (Poster) Clinicopathologic Profile of Filipino Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer: A Single Institution Review
|
|
PP01.72 (Poster) Trial in Progress: Randomized Phase 3 Study of Tarlatamab, a DLL3-Targeting BiTE® (Bispecific T-cell Engager) Immunotherapy, Compared to Standard of Care in Patients With Relapsed Small Cell Lung Cancer (DeLLphi-304)
|
|
PP01.74 (Poster) LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study
|
|
PP01.76 (Poster) Optimizing Biomarker Models for Biologically-Heterogeneous Cancers: A Nested Model Approach for Lung Cancer
|
|
PP01.77 (Poster) Biomarker testing in lung cancer: perspectives and challenges concerning internal, external and reflexive testing processes in an academic medical center
|
|
PP01.78 (Poster) First-line nivolumab + ipilimumab + chemotherapy in metastatic non-small cell lung cancer: CheckMate 9LA 4-year clinical update
|
|
PP01.78 Faris Badin Abstract
|
|
PP01.79 (Poster) ctDNA dynamics, prognostic markers, and RESULTS mechanisms of resistance in tepotinib-treated MET exon 14 skipping (METex14) NSCLC in the VISION trial
|
|
PP01.80 (Poster) A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK+ non-small celllung cancer (NSCLC) treated with ALK inhibitors
|
|
PP01.81 (Poster) REZILIENT2: Phase 2 Study of Zipalertinib in Patients With Advanced NSCLC With Exon 20 Insertions and Other Uncommon EGFR Mutations
|
|
PP01.8 (Poster) Tumor-naïve pre-surgical ctDNA detection is prognostic in stage I lung adenocarcinoma, associating with PD-L1 positivity and high-grade histological subtype
|
|
PP01.83(Poster) Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
|
|
PP01.84 (Poster) Tepotinib + osimertinib in EGFR mutant NSCLC with MET amplification following 1L osimertinib: INSIGHT 2 primary analysis
|
|
PP01.85 (Poster) A Phase 2/3 Study of Fianlimab, Cemiplimab, plus Chemotherapy Versus Cemiplimab plus Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer
|
|
PP01.86 (Poster) Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC
|
|
PP01.88 (Poster) REZILIENT3: Phase 3 Study of Zipalertinib Plus Chemotherapy in Previously Untreated, Advanced, Nonsquamous NSCLC Patients With EGFR Exon 20 Insertions
|
|
PP01.89 (Poster) Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC
|
|
PP01.90 (Poster) Real-world demographics, clinical characteristics, treatment patterns and clinical outcomes for US patients with limited-stage small-cell lung cancer
|
|
PP01.91 (Poster) Repotrectinib in patients with ROS1 fusion‑positive non‑small cell lung cancer: update from the pivotal phase 1 / 2 TRIDENT‑1 trial
|
|
PP01.92 (Poster) Analytical Performance of a Cell-free DNA Targeted Methylation Test for Early Lung Adenocarcinoma (LUAD) Recurrence Prediction
|
|
PP01.93 (Poster) RET Fusion as a Treatable Resistance Mechanism in EGFR Mutation Lung Cancer - A Case Report
|
|
PP01.95 (Poster) STK11, KEAP1, and KRAS mutation epidemiology and real-world outcomes in US patients with newly diagnosed metastatic non-small cell lung cancer
|
|
PP01.96 (Poster) Characterization of DNA damage repair mutations in lung cancer in an underserved urban patient population
|
|
PP01.97 (Poster) Real-World Treatment Patterns Among Resected Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Atezolizumab
|
|
PP01.99 (Poster) Switching to Subcutaneous Atezolizumab After Intravenous Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling
|
|
PP01.001 Margaret Locke Abstract
|
|
PP01.002 Antonious Hazim Abstract
|
|
PP01.026 David Xiao Abstract
|
|
PP01.041 Christopher Zazueta NACLC23 Abstract
|
|
PP01.042 Kelsey Pan NACLC23 Abstract
|
|
PP01.044 Fadila Zerka NACLC23 Abstract
|
|
PP01.046 Aida Myftiu NACLC Abstract
|
|
PP01.047 Palina Woodhouse NACLC23 Abstract
|
|
PP01.050 Zofia Piotrowska NACLC23 Abstract
|
|
PP01.052 Tyler Faith NACLC23 Abstract
|
|
PP01.053 Winston Gouldin NACLC23 Abstract
|
|
PP01.054 Jun Zhang Abstract
|
|
PP01.055 Frank Weinberg NACLC23 Abstract
|
|
PP01.057 Subhadeep Das NACLC23 Abstract
|
|
PP01.058 Qingqing Xu NACLC23 Abstract
|
|
PP01.059 Mary Gwin NACLC23 Abstract
|
|
PP01.060 Vershalee Shukla NACLC23 Abstract
|
|
PP01.061 Vershalee Shukla NACLC23 Abstract
|
|
PP01.063 Vivian Altiery De Jesus NACLC Abstract
|
|
PP01.064 Maxwell Akanbi NACLC23 Abstract
|
|
PP01.065 Justin Cheung NACLC23 Abstract
|
|
PP01.066 Shruti_Gupta_NACLC23_Abstract
|
|
PP01.067 Xiao Hu NACLC23 Abstract
|
|
PP01.068 Alexander Spira NACLC23 Abstract
|
|
PP01.069 Sarah Waliany NACLC23 Abstract
|
|
PP01.070 Sylvia Yong NACLC23 Abstract
|
|
PP01.071 Kenneth Samala NACLC23 Abstract
|
|
PP01.072 Hossain Borghaei NACLC23 Abstract
|
|
PP01.074 Jens Samol NACLC23 Abstract
|
|
PP01.076 Palina Woodhouse NACLC23 Abstract
|
|
PP01.077 Marie Dreyer NACLC23 Abstract
|
|
PP01.080 Josh Biber NACLC23 Abstract
|
|
PP01.081 John Heymach NACLC23 Abstract
|
|
PP01.082 Tae Hee Hong NACLC23 Abstract
|
|
PP01.083 Matthew Lee_NACLC23 Abstract
|
|
PP01.084 Richard O' Hara_NACLC23 Abstract
|
|
PP01.088 John Heymach NACLC23 Abstract
|
|
PP01.090 Anne Chiang NACLC Abstract
|
|
PP01.092 Mahami Roychowdhury-Saha Abstract
|
|
PP01.093 Vivek Athipatla NACLC23 Abstract
|
|
PP01.094 Arvind Kumar NACLC2023 Abstract
|
|
PP01.095 Daniel Simmons NACLC23 Abstract
|
|
PP01.096 Jeremy Kao NACLC23 Abstract
|
|
PP01.097 Husam_Albarmawi_NACLC23_Abstract
|
|
PP01.098 Charles Logan NACLC23 Abstract
|
|
PP01.099 Stephanie Liu Abstract
|
|
PP01.100 Daniel Principe Abstract
|
|
PP01.101 Paul Lozowicki Abstract
|
|
PP01.102 Sabrina Thomas NACLC Abstract
|
|
PP01.104 Peony Yu Abstract
|
|
PP01.105 Melissa Santorelli Abstract
|
|
PP01.106 Brandi Oakley Abstract
|
|
PP01.107 Jesse Sussell Abstract
|
|
PP01.108 Mariana Borras Osorio Abstract
|
|
PP01.109 Lauren Lentini Abstract
|
|
PP01.110 Umit Tapan NACLC23 Abstract
|
|
PP01.112 Davey Daniel NACLC23 Abstract
|
|
PP01.114 Zaid Al-Saheli NACLC23 Abstract
|
|
PP01.115 Christina Baik NACLC Abstract
|
|
PP01.116 Reina Haque NACLC23 Abstract
|
|
PP01.117 Apar Ganti NACLC23 Abstract
|
|
PP01.119 Firas Badin NACLC23 Abstract
|
|
PP01.120 Patrick_Meyers_NACLC23_Abstract
|
|
PP01.121 Kim Lauer NACLC23 Abstract
|
|
PP01.122 Ivy Riano NACLC23 Abstract
|
|
PP01.124 Danielle Dressler NACLC23 Abstract
|
|
PP01.126 Raymond Osarogiagbon Abstract
|
|
PP01.128 Seana Corbin NACLC23 Abstract
|
|
PP01.129 Eric Toloza NACLC23 Abstract (PreopHematocrit)
|
|
PP01.130 Eric Toloza NACLC23 Abstract (PostopHematocrit)
|
|
PP01.131 Eric Toloza NACLC23 Abstract (LCRI)
|
|
PP01.132 Yaqi Miao NACLC23 Abstract
|
|
PP01.133 Kate Lovett NACLC23 abstract
|
|
PP01.134 Michelle Shiller NACLC23 Abstract
|
|
PP01.135 Philip Young NACLC23 Abstract
|
|
PP01.136 Beom-joon Lee NACLC23 Abstract
|
|
PP01.137 Priyanka Reddy NACLC23 Abstract
|
|
PP01.138 Kelly Meza Abstract
|
|
PP01.140 Eileen Curran NACLC23 Abstract
|